The startup's technology uses generative AI to automate the process of creating and testing new mRNA sequences, a task traditionally done manually by scientists. Inceptive is already collaborating with a major European pharmaceutical company to develop an mRNA vaccine for a new infectious disease. The company plans to offer its software as a service to any entity developing mRNA and later RNA medicines.
Key takeaways:
- Inceptive, an AI-powered biotech startup, has raised $100 million from Nvidia’s NVentures, Andreessen Horowitz and Obvious Ventures, bringing its total financing to $120 million.
- The startup, founded by former Google AI researcher Jakob Uszkoreit, is developing an AI platform that designs unique mRNA sequences, aiming to automate and streamline the process of creating and testing new molecular structures.
- Inceptive is already collaborating with a major European pharmaceutical company to develop an mRNA vaccine for a new infectious disease, and plans to provide their software to any entity developing mRNA and later RNA medicines.
- While it's still early to determine the effectiveness of generative AI in healthcare, Inceptive's partnership with a leading pharmaceutical company suggests potential in this area.